Oncology

Molecular Methodologies & Technologies

Strategies and Challenges of Measurable Residual Disease Testing in Acute Myeloid Leukemia

Program Committee Moderator(s)

• AB

  Amir Behdad, MD, MBA (he/him/his)

  Professor and Regional Chair of Pathology
  Cleveland Clinic Florida
  Weston, Florida, United States

Co-Moderator (Early Career)(s)

• BZ

  Bing Zhang, MD (she/her/hers)

  Clinical Associate Professor
  Stanford University School of Medicine
  Palo Alto, California, United States

Session

Description: Measurable residual disease (MRD) has been shown to be a valuable prognostic marker in patients with acute myeloid leukemia (AML), however, designing a comprehensive AML MRD assay is fraught with technical challenges due to the complexity of AML biology. Some individual targets, such as NPM1 and/or specific recurrent fusions, may serve as adequate MRD markers for a subset of AML, however, other MRD strategies are warranted for other cases. This session will discuss the various strategies for MRD analysis and highlight some of the challenges and pitfalls.

If this session topic is of interest to you, please consider looking at the following course on AMP EDucation (AMPED™ Online)

Title: Emerging and Evolving Biomarkers: MRD
FLT3 mutations and AML: Recent findings, laboratory considerations, and clinical implications
Click here to learn more.
Click here to learn more.

Presentations:

• 10:15 AM – 11:00 AM PST

  Quantification of Measurable Residual Disease in Adults with Acute Myeloid Leukemia
  

  Breakout Speaker: Christopher S. Hourigan, DM DPhil (he/him/his) – Virginia Tech FBRI Cancer Research Center
• 11:00 AM – 11:45 AM PST

  AML MRD Analysis Using FLT3-ITD
  

  Breakout Speaker: Mark Levis, MD PhD – Johns Hopkins